证券代码：002412 证券简称：汉森制药 公告编号：2025-006 湖南汉森制药股份有限公司 第六届董事会第七次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 湖南汉森制药股份有限公司（以下简称"公司"）第六届董事会第七次会议 于 2025 年 4 月 24 日在公司一楼会议室以现场方式召开，本次会议由公司董事 长刘正清先生召集并主持，会议通知于 2025 年 4 月 14 日以专人递送、传真及 电子邮件等方式送达给全体董事、监事和高级管理人员。本次会议应参加会议董 事 7 人，实际参加会议董事 7 人，公司监事、高级管理人员列席了本次会议。本 次会议的召集、召开符合《中华人民共和国公司法》及《公司章程》的规定。 二、董事会会议审议情况 （一）审议通过了《2024 年度总裁工作报告》 表决结果：7 票赞成；0 票弃权；0 票反对。 （二）审议通过了《2024 年度董事会工作报告》 《2024 年度董事会工作报告》具体内容详见同日公司指定信息披露网站巨 潮资讯（www.cninfo.com.cn）。 公司独立董事分别 ...

证券代码：002412 证券简称：汉森制药 公告编号：2025-009 湖南汉森制药股份有限公司 关于 2024 年度拟不进行利润分配的专项说明 二、利润分配的基本情况 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 湖南汉森制药股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召 开第六届董事会第七次会议及第六届监事会第七次会议，审议通过了《2024 年 度利润分配预案》，本事项尚需提交公司 2024 年度股东大会审议，现将相关事 宜公告如下： 一、审议程序 （一）审计委员会审议情况 公司董事会审计委员会 2025 年第二次会议审议通过《2024 年度利润分配 预案》，与会委员认为该利润分配预案符合公司实际情况及《公司章程》规定， 未发现有损害股东特别是中小股东的情形，同意本年度利润分配预案。 （二）董事会审议情况 董事会认为：公司利润分配预案兼顾了公司现有及未来投资资金需求、经营 资金周转等实际情况，符合《公司法》和《公司章程》的规定，未损害公司股东 尤其是中小股东的利益，有利于公司的正常经营和健康发展，同意将《2024 年 度利润分配预 ...

汉森制药（002412）公告，2025年第一季度营业收入2.69亿元，同比增长6.00%。净利润1125.72万元， 同比减少80.68%。 ...

汉森制药（002412）公告，2024年营业收入10.04亿元，同比增长5.12%。归属于上市公司股东的净利润 2.2亿元，同比增长7.43%。基本每股收益0.4377元/股，同比增长7.44%。公司计划不派发现金红利，不 送红股，不以公积金转增股本。 ...

Revenue and Profit - The company's revenue for Q1 2025 was ¥269,286,565.75, representing a 6.00% increase compared to ¥254,032,546.62 in the same period last year[4] - Net profit attributable to shareholders decreased by 80.68% to ¥11,257,164.35 from ¥58,264,674.17 year-on-year[4] - Basic and diluted earnings per share dropped by 80.66% to ¥0.0224 from ¥0.1158 year-on-year[4] - Net profit for the current period was ¥11,257,164.35, a significant decrease of 80.7% from ¥58,264,674.17 in the previous period[20] - Other comprehensive income after tax for the current period was -¥21,337,283.83, compared to ¥6,133,860.08 in the previous period[20] - The total comprehensive income for the current period was -¥10,080,119.48, a decrease from ¥64,398,534.25 in the previous period[20] Cash Flow - The net cash flow from operating activities increased by 140.97% to ¥49,407,081.75, up from ¥20,503,807.95 in the previous year[4] - Operating cash flow for the current period is ¥49,407,081.75, a significant increase from ¥20,503,807.95 in the previous period, reflecting a growth of approximately 141.5%[21] - Total cash inflow from investment activities is ¥297,965,601.16, compared to ¥185,560,117.38 in the previous period, indicating an increase of about 60.5%[21] - Cash outflow for investment activities reached ¥386,746,011.20, up from ¥184,230,522.44, resulting in a net cash flow from investment activities of -¥88,780,410.04, compared to a positive ¥1,329,594.94 previously[21] - The company reported a decrease in cash flow from financing activities, with a net cash flow of -¥360,475.00 compared to a positive ¥1,831,534.64 in the previous period[22] - Cash and cash equivalents at the end of the period stand at ¥86,814,834.11, an increase from ¥74,792,141.37 in the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,546,113,612.79, a slight decrease of 0.04% from ¥2,547,234,247.32 at the end of the previous year[4] - Total liabilities increased to ¥352,811,672.12 from ¥343,852,187.17, marking a rise of 2.8%[18] - The company's total equity attributable to shareholders decreased by 0.46% to ¥2,193,301,940.67 from ¥2,203,382,060.15 at the end of the previous year[4] - Long-term equity investments decreased from ¥855,753,806.92 to ¥787,701,027.88, a reduction of approximately 7.9%[16] - Total current assets increased from ¥1,123,168,939.47 to ¥1,199,045,999.11, reflecting a growth of about 6.8%[16] Expenses - Management expenses increased by 56.21% to ¥19,155,983.25, attributed to higher costs related to annual meetings and business hospitality[8] - Research and development expenses for the current period were ¥9,330,205.66, compared to ¥7,885,856.79, indicating a growth of 18.3%[19] - Total operating costs amounted to ¥201,370,449.78, up from ¥193,715,774.24, reflecting a rise of 3.4%[19] - The company experienced a 341.89% increase in other operating expenses, totaling ¥466,337.46, primarily due to the write-off of biological assets[9] Shareholder Information - Hainan Hansen Holdings holds 42.13% of the shares, making it the controlling shareholder of the company[13] - The number of shares held by the top ten shareholders includes significant stakes from Hainan Hansen Holdings and Shanghai Fosun Pharmaceutical, with the latter holding 4.82%[13] - The company has a total of 212,006,189 shares held by Hainan Hansen Holdings, which are unrestricted[13] Inventory and Receivables - Inventory decreased from ¥222,876,023.84 to ¥212,211,507.99, a decline of about 4.8%[16] - The company reported accounts receivable increased from ¥287,184,352.67 to ¥339,164,828.32, an increase of approximately 18.1%[16] - The total amount of other current assets decreased from ¥80,872,548.44 to ¥76,139,117.21, a decline of about 5.4%[16] Other Information - The company has not yet audited the first quarter report, indicating that the figures may be subject to change[23] - The company will implement new accounting standards starting in 2025, which may affect future financial reporting[24]

Financial Performance - The company's operating revenue for 2024 was ¥1,004,469,462.29, representing a 5.12% increase compared to ¥955,530,797.42 in 2023[17]. - The net profit attributable to shareholders for 2024 was ¥220,244,409.11, up 7.43% from ¥205,014,883.78 in 2023[17]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥211,153,898.06, a 2.89% increase from ¥205,216,869.31 in 2023[17]. - The basic earnings per share for 2024 was ¥0.4377, reflecting a 7.44% increase from ¥0.4074 in 2023[17]. - The total assets at the end of 2024 were ¥2,547,234,247.32, a 9.02% increase from ¥2,336,488,623.93 at the end of 2023[17]. - The net assets attributable to shareholders at the end of 2024 were ¥2,203,382,060.15, up 12.24% from ¥1,963,028,938.67 at the end of 2023[17]. - The cash flow from operating activities for 2024 was ¥130,783,795.99, a decrease of 18.74% compared to ¥160,946,071.17 in 2023[17]. - The weighted average return on equity for 2024 was 10.57%, down from 11.54% in 2023[17]. - The company reported a total non-operating income of 9,090,511.05 in 2024, a significant recovery from a loss of 201,985.53 in 2023[23]. - Government subsidies recognized in the current period amounted to 6,122,286.14 in 2024, up from 4,028,779.66 in 2023[23]. Research and Development - The company plans to continue investing in R&D to enhance product development and expand its product portfolio, focusing on generics and innovative drugs[28]. - The product research and development saw the registration of Englitazone tablets 25mg and progress in clinical trials for Tianma Wake Brain[45]. - The company intends to increase R&D investment and accelerate new product development, aiming for deeper integration with research institutions and universities[71]. - The number of R&D personnel decreased by 9.68% to 196, with the proportion of R&D personnel in the total workforce dropping to 11.70%[58]. - Research and development expenses for 2024 were ¥39,322,290.36, a decrease of 11.5% from ¥44,479,163.31 in 2023[186]. Market Position and Strategy - The company has established itself as a leading player in the pharmaceutical manufacturing industry, recognized as a provincial-level enterprise technology center in Hunan[28]. - The company has exclusive production rights for four proprietary products and five unique dosage forms, enhancing its market position[28]. - The company’s main products include traditional Chinese medicine and chemical drugs, addressing various health conditions such as digestive and cardiovascular issues[30]. - The marketing strategy focuses on leveraging product strengths and optimizing channel management to enhance market presence and capture additional market share[41]. - The company has successfully participated in multiple centralized procurement projects, securing qualifications for various products, including "Si Mo Tang Oral Liquid" and "Ginkgo Leaf Capsules" in significant procurement initiatives[37]. Operational Efficiency - The company has established a comprehensive procurement management system, enhancing supplier management and reducing procurement costs through competitive bidding and strategic sourcing[34]. - The production model is market-oriented, ensuring sufficient supply while maintaining reasonable inventory levels, with a focus on lean production to improve efficiency and reduce costs[36]. - The company launched a lean marketing management upgrade project to enhance value creation and maintenance[44]. - The company initiated the second phase of lean production projects, focusing on data collection and evaluation analysis[45]. - The company emphasizes a collaborative approach among departments to improve marketing execution and enhance overall management capabilities[36]. Governance and Compliance - The company maintains an independent business system and operates independently from its controlling shareholders in all aspects, including personnel, assets, and finance[84]. - The company has established a transparent performance evaluation system for directors and senior management, ensuring clear incentives and penalties[82]. - The company has a dedicated internal audit department that supervises daily operations and major related transactions[82]. - The company emphasizes information disclosure and investor relations, ensuring timely and accurate communication with all investors[82]. - The company has a complete governance structure that complies with the requirements of the China Securities Regulatory Commission[79]. Environmental and Social Responsibility - The company emphasizes green production and has implemented measures to reduce carbon emissions, including water resource recycling and wastewater treatment[120]. - The company has increased investment in environmental protection technology upgrades, effectively reducing pollution emissions during production[123]. - The company made a donation of 30,000 yuan to support poverty alleviation and rural revitalization efforts in Yiyang City[124]. - The company provides a good working environment and various social insurances for employees, emphasizing talent development and safety training[122]. Shareholder Relations - The company has established a three-year shareholder return plan (2024-2026) to enhance its dividend decision-making and supervision mechanism[109]. - The company ensures that minority shareholders have the opportunity to express their opinions and that their legal rights are protected[110]. - The company held its annual general meeting with a participation rate of 43.86% on May 21, 2024, where nine resolutions were passed, including the 2023 Board of Directors' work report[85]. - The company has fulfilled all commitments made by its actual controllers, shareholders, and related parties during the reporting period[126]. Financial Management - The total pre-tax remuneration for the board of directors, supervisors, and senior management amounted to RMB 503.26 million[97]. - The company has a remuneration system that aligns with its operational performance and individual performance[95]. - The company has established a comprehensive internal control system in accordance with relevant laws and regulations[113]. - The internal control evaluation report indicates that the company maintained effective financial reporting internal controls as of December 31, 2024[117]. - The company has not reported any penalties from securities regulatory authorities for its directors and supervisors in the past three years[94].

湖南汉森制药股份有限公司关于购买房产暨关联交 易的进展公告 二、交易进展情况 2023年4月，三银地产办理了前述房屋的权属变更登记手续。后公司在房屋验收过程中提出了整改 意见，双方于近日完成房屋的最终验收及交付，三银地产向公司移交了长沙市自然资源和规划局颁发的 《中华人民共和国不动产权证书》。本次购买房产事项已全部结束。 三、备查文件 《中华人民共和国不动产权证书》 湖南汉森制药股份有限公司 董事会 2025年3月22日 本公司及全体董事保证公告内容真实、准确和完整，不存在虚假记载、误导性陈述或者重大遗漏。 一、基本情况 湖南汉森制药股份有限公司（以下简称"公司"）于2020年9月27日召开第五届董事会第五次会议审 议并通过了《关于购买房产暨构成关联交易的议案》，同意公司向参股公司长沙三银房地产开发有限公 司（以下简称"三银地产"）购买位于湖南省长沙市岳麓区潇湘北路1227号建设的三湘一品项目（C栋） 共7层14套（901至1502）房产和配套的42个室内停车位。房屋建筑面积5,405.33平方米（未包括车位面 积），交易总价为人民币11,750.20万元。具体内容详见公司2020年9月29日刊登于巨潮资讯网 ...

证券代码：002412 证券简称：汉森制药 公告编号：2025-005 湖南汉森制药股份有限公司 关于购买房产暨关联交易的进展公告 本公司及全体董事保证公告内容真实、准确和完整，不存在虚假记载、误导性陈 述或者重大遗漏。 一、基本情况 湖南汉森制药股份有限公司（以下简称"公司"）于 2020 年 9 月 27 日召开第五 届董事会第五次会议审议并通过了《关于购买房产暨构成关联交易的议案》，同意公 司向参股公司长沙三银房地产开发有限公司（以下简称"三银地产"）购买位于湖南 省长沙市岳麓区潇湘北路 1227 号建设的三湘一品项目（C 栋）共 7 层 14 套（901 至 1502）房产和配套的 42 个室内停车位。房屋建筑面积 5,405.33 平方米（未包括车位 面积），交易总价为人民币 11,750.20 万元。具体内容详见公司 2020 年 9 月 29 日刊 登于巨潮资讯网（www.cninfo.com.cn）上的《关于购买房产暨构成关联交易的公告》 （公告编号：2020-052）。公司于 2020 年 10 月 15 日召开 2020 年第二次临时股东 大会审议并通过了该项议案。 2021 年 6 月 ...

关于四磨汤口服液获批国家中药保护品种 延长保护期的公告 本公司及全体董事保证公告内容真实、准确和完整，不存在虚假记载、误导 性陈述或者重大遗漏。 近日，国家药品监督管理局（以下简称 "国家药监局"）网站发布《关于 中药保护品种公告（延长保护期第 21 号）（2025 年第 20 号）》，经国家中药 品种保护审评委员会组织的委员审评，国家药监局核准，对湖南汉森制药股份有 限公司（以下简称"公司"）的四磨汤口服液继续给予二级保护。现将相关情况 公告如下： 一、药品基本信息 药品名称：四磨汤口服液 剂型：合剂 功能主治：顺气降逆，消积止痛。用于婴幼儿乳食内滞证，症见腹胀、腹痛、 啼哭不安、厌食纳差、腹泻或便秘；中老年气滞、食积证，症见脘腹胀满、腹痛、 便秘；以及腹部手术后促进肠胃功能的恢复。 证券代码：002412 证券简称：汉森制药 公告编号：2025-004 湖南汉森制药股份有限公司 保护期限：自 2025 年 2 月 24 日起至 2032 年 2 月 25 日止 二、其他相关情况 四磨汤口服液为公司独家品种，是《国家基本医疗保险、工伤保险和生育保 险药品目录（2024 年）》乙类产品。 本次国家药监局核准对 ...

证券代码：002412 证券简称：汉森制药 公告编号：2025-003 湖南汉森制药股份有限公司 关于变更签字会计师的公告 本公司及全体董事保证公告内容真实、准确和完整，不存在虚假记载、误 导性陈述或者重大遗漏。 湖南汉森制药股份有限公司（以下简称"公司"）于 2024 年 10 月 25 日、 2024 年 11 月 19 日分别召开了第六届董事会第六次会议和 2024 年第一次临时 股东大会，审议通过了《关于公司拟续聘 2024 年度审计机构的议案》，同意续 聘中审众环会计师事务所（特殊普通合伙）（以下简称"中审众环"）为公司 2024 年度审计机构。 上述事项具体情况详见公司于 2024 年 10 月 29 日及 2024 年 11 月 20 日在 《证券时报》《中国证券报》《上海证券报》《证券日报》和巨潮资讯网 （www.cninfo.com.cn）上披露的相关公告，公告编号为 2024-019、2024-024。 近日，公司收到中审众环出具的《关于变更湖南汉森制药股份有限公司签字 会计师的告知函》。现将相关情况公告如下： 一、本次变更签字注册会计师的情况 中审众环作为公司 2024 年度财务报告和内 ...